NEWARK, Del., March 7, 2012 /PRNewswire/ -- iBio, Inc.
(NYSE AMEX: IBIO) will be presenting at the ROTH Capital Partners
24th Annual Conference. The conference will take place on
March 11-14, 2012 in Dana Point, California.
Robert Erwin, President of iBio,
will present an update on the Company's business and strategy on
Wednesday, March 14 at 9:00 a.m. Investors attending the conference who
would like to schedule a one-on-one meeting with Mr. Erwin should
contact their ROTH Capital representative directly.
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch™
platform, providing collaborators full support for turn-key
implementation of its technology for both proprietary and
biosimilar products. The iBioLaunch platform is a proprietary,
transformative technology for development and production of
vaccines and therapeutic proteins using transient gene expression
in green plants. The technology has been applied successfully to
proteins difficult or impossible to produce with other methods, as
well as proteins representative most important classes of biologic
pharmaceuticals. Advantages of the iBioLaunch platform over other
systems include enablement of rapid development and validation of
modular, scalable, and optionally robotic, multi-product
manufacturing facilities; production time measured in weeks instead
of months or more; product entry that is unconstrained by
traditional process patents; and significantly lower capital and
operating costs for comparable production. Further information is
available at: www.ibioinc.com.
About ROTH Capital Partners, LLC
ROTH Capital Partners, LLC (ROTH) is a relationship-driven
investment bank focused on identifying growth opportunities for
corporate and institutional clients. As a full-service investment
bank, ROTH provides capital raising, M&A advisory, analytical
research, trading and market-making services. Headquartered in
Newport Beach, CA, ROTH is
privately-held and owned by its employees, and maintains offices
throughout the U.S., Hong Kong and
a Shanghai Representative Office.
For more information on ROTH, please visit www.roth.com.
Forward-Looking Statements
Statements included in this news release related to iBio,
Inc. may constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the Company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects. Further information on potential risk factors
that could affect the Company's financial results can be found in
the company's Reports filed with the Securities and Exchange
Commission.
Contacts:
|
|
|
|
Corporate:
|
Investor:
|
|
|
Robert
Erwin,
President
|
Douglas
Beck, CFO
|
iBio,
Inc.
|
iBio,
Inc.
|
302-355-2335
|
302-355-9452
|
rerwin@ibioinc.com
|
ir@ibioinc.com
|
SOURCE iBio, Inc.